SCHEMBL2024432

SCHEMBL2024432

Clc1ccccc1-c1nnc(-c2cn3c4c(cccc24)CCC3)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.51
NPC1 O15118 7/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HPGD P15428 4/20 0.51
TP53 P04637 3/20 0.51
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 5/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
PARP1 P09874 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017975 0.89 NPC1 (0.47) RAB9ANPC1SMN1; SMN2HPGDTP53
SCHEMBL2021179 0.88 RAB9A (0.51) RAB9ANPC1SMN1; SMN2HPGDTP53
SCHEMBL2016789 0.88 HTR2A (0.44) RAB9ANPC1SMN1; SMN2HPGDHTR2A
SCHEMBL2016603 0.87 HTR2A (0.46) RAB9ANPC1HPGDHTR2AHTR2C
SCHEMBL2021453 0.86 RAB9A (0.49) RAB9ANPC1SMN1; SMN2HPGDHTR2A
SCHEMBL2015858 0.86 RAB9A (0.48) RAB9ANPC1SMN1; SMN2HPGDTP53
SCHEMBL2018600 0.82 HTR2A (0.46) HPGDTP53HTR2AHTR2CALDH1A1
SCHEMBL2019352 0.81 NPC1 (0.46) RAB9ANPC1SMN1; SMN2HPGDTP53
SCHEMBL2020405 0.81 NPC1 (0.43) RAB9ANPC1SMN1; SMN2HPGDHTR2A
SCHEMBL2020602 0.81 NPC1 (0.44) RAB9ANPC1SMN1; SMN2HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 RAB9A 1649/4885NPC1 235/4885SMN1; SMN2 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.